Cancer Treatment Reviews

Papers
(The H4-Index of Cancer Treatment Reviews is 47. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook525
Review of precision cancer medicine: Evolution of the treatment paradigm306
Immunotherapy for pancreatic cancer: A 2020 update251
Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors – A systematic review and meta-analysis178
The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target160
MYC as a target for cancer treatment155
Biomarkers for immunotherapy response in head and neck cancer142
KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?136
KRAS: From undruggable to a druggable Cancer Target127
How did lomustine become standard of care in recurrent glioblastoma?112
Adenocarcinoma spectrum lesions of the lung: Detection, pathology and treatment strategies106
The role of autophagy in resistance to targeted therapies87
Targeting the PI3K pathway and DNA damage response as a therapeutic strategy in ovarian cancer85
MSI as a predictive factor for treatment outcome of gastroesophageal adenocarcinoma85
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis85
Targeting FGFR inhibition in cholangiocarcinoma83
Microsatellite instability in Gastric Cancer: Between lights and shadows83
BAP1: Not just a BRCA1-associated protein82
MEK inhibitor resistance mechanisms and recent developments in combination trials82
The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal80
Treatment landscape of metastatic pancreatic cancer79
KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures78
Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality77
Cancer and COVID-19: Unmasking their ties75
Real world data in the era of Immune Checkpoint Inhibitors (ICIs): Increasing evidence and future applications in lung cancer74
EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins73
Testicular cancer: Determinants of cisplatin sensitivity and novel therapeutic opportunities70
Current standards and future perspectives in adjuvant treatment for biliary tract cancers69
Global challenges and policy solutions in breast cancer control69
Challenges in the treatment of gastric cancer in the older patient68
HER2-positive advanced breast cancer treatment in 202065
The role of exosomes in metastasis and progression of melanoma62
Targeting ARID1A mutations in cancer61
Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy59
Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)–related interstitial lung disease/pneumonitis—Focus on proactive monitoring, diagnosis, and management58
SARS-CoV-2 and cancer: Are they really partners in crime?58
Evolving role of regorafenib for the treatment of advanced cancers58
Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives55
Breast implant-associated anaplastic large cell lymphoma: A comprehensive review54
NRAS mutant melanoma: Towards better therapies53
Impact of high tumor mutational burden in solid tumors and challenges for biomarker application53
Immunotherapy in non-small cell lung cancer harbouring driver mutations51
Parathyroid cancer: An update50
Melanoma brain metastases – Interdisciplinary management recommendations 202049
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping49
How to measure tumour response in rectal cancer? An explanation of discrepancies and suggestions for improvement47
Thymic epithelial tumors: From biology to treatment47
0.027070045471191